41889
document
Nizatidine versus ranitidine in the treatment of peptic ulcer disease : report on the Dutch investigation as part of a European multicentre trial . The efficacy and safety of nizatidine was evaluated in comparison with ranitidine in 230 patients with endoscopically documented gastric ( 71 ) or duodenal ( 159 ) ulcers . Gastric ulcer patients who satisfied all criteria for inclusion and exclusion were randomly allocated to nizatidine 300 mg nocte , 150 mg b.d . or ranitidine 150 mg b.d. , duodenal ulcer patients to nizatidine 300 mg nocte or ranitidine 300 mg nocte . Endoscopic healing was defined as complete epithelialisation of all mucosal lesions . Endoscopy was performed at 4 and , if not healed , at 8 weeks . Healing rates were shown to be comparable for all treatment regimens . In both duodenal ulcer treatment groups , and with both drugs , healing was negatively influenced by ulcer size , ulcer number , smoking habits and a disease duration of 5 years or more . Few side effects were noted . Nizatidine , administered as a 300 mg nocte and as a 150 mg b.d . dose appeared to be a safe H2 antagonist and was as effective as ranitidine in the treatment of duodenal and gastric ulceration .
41890
Intervention_Pharmacological
Nizatidine
41891
Intervention_Pharmacological
ranitidine
41892
Intervention_Pharmacological
nizatidine
41893
Intervention_Pharmacological
ranitidine
41894
Intervention_Pharmacological
nizatidine 300 mg nocte , 150 mg b.d . or ranitidine 150 mg
41895
Intervention_Pharmacological
nizatidine 300 mg nocte or ranitidine 300 mg nocte .
41896
Intervention_Pharmacological
Nizatidine
41897
Intervention_Pharmacological
ranitidine
41898
Outcome_Other
efficacy and safety
41899
Outcome_Physical
Endoscopic healing
41900
Outcome_Physical
complete epithelialisation of all mucosal lesions
41901
Outcome_Physical
Healing rates
41902
Outcome_Physical
healing
41903
Outcome_Physical
ulcer size
41904
Outcome_Physical
ulcer number
41905
Outcome_Physical
smoking habits
41906
Outcome_Physical
disease duration
41907
Outcome_Adverse-effects
Few side effects
41908
Outcome_Other
effective
41909
Participant_Sample-size
230
41910
Participant_Condition
gastric
41911
Participant_Sample-size
71
41912
Participant_Condition
duodenal
41913
Participant_Sample-size
159
41914
Participant_Condition
ulcers
41915
Participant_Condition
Gastric ulcer
41916
Participant_Condition
duodenal and gastric ulceration .